Fulgent Genetics Inc.
Fulgent Genetics Inc. (FLGT): 5 pipeline candidates · ~17 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.4 months
D/E 0.11 · 7% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for Fulgent Genetics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$502.7M
Cash
$23.5M
Quarterly Burn
$56.1M
Runway
17.4 mo
Revenue
$71.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| Antibody drug conjugate (ADC) candidates | Preclinical |
| Enfortumab Vedotin | Phase 4 |
| FID-007 | Phase 2 |
| FID-022 | Phase 1 |
| FID007 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
157
Total value held
$271.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,774,519 | $44.1M |
| vanguard capital management llc | 1,760,300 | $28.0M |
| rtw investments, lp | 1,289,000 | $20.5M |
| dimensional fund advisors lp | 671,664 | $10.7M |
| invenomic capital management lp | 610,318 | $9.7M |
| geode capital management, llc | 584,207 | $9.3M |
| ameriprise financial inc | 563,375 | $9.0M |
| state street corp | 529,399 | $8.4M |
| d. e. shaw & co., inc. | 486,770 | $7.7M |
| jpmorgan chase & co | 460,363 | $7.2M |
Showing top 10 of 157 institutional holders of Fulgent Genetics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Fulgent Genetics Inc.'s pipeline?
Fulgent Genetics Inc. (FLGT) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fulgent Genetics Inc.'s lead drug candidate?
Fulgent Genetics Inc.'s most advanced tracked candidate is Antibody drug conjugate (ADC) candidates (Preclinical) for Preclinical activity observed against different tumors with a broad range of target antigen expression levels; ADCs to novel targets are being prepared with the goal of generating candidates for clinical studies..
What is Fulgent Genetics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fulgent Genetics Inc. has approximately 17.4 months of cash runway.
What is Fulgent Genetics Inc.'s market capitalization?
Fulgent Genetics Inc.'s market capitalization is approximately $502.7M.
Who is the CEO of Fulgent Genetics Inc.?
Mr. Ming Hsieh is the chief executive officer of Fulgent Genetics Inc. (FLGT).
Get the full picture on Fulgent Genetics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.